(Q37235024)

19 August 2017

1 reference

title

Somatic pharmacogenomics in cancer (English)

1 reference

19 August 2017

1 reference

O N Ikediobi

1

1 reference

19 August 2017

5 August 2008

1 reference

The Pharmacogenomics Journal

19 August 2017

1 reference

19 August 2017

8

1 reference

19 August 2017

305-314

1 reference

19 August 2017

5

1 reference

https://scigraph.springernature.com/pub.10.1038/tpj.2008.8

19 August 2017

0 references

cites work

Transcriptomic analysis of the NCI-60 cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Pharmacogenomics: bench to bedside

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Insights, challenges, and future directions in irinogenetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Tamoxifen pharmacogenomics: the role of CYP2D6 as a predictor of drug response

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Should DPD analysis be required prior to prescribing fluoropyrimidines?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mechanisms of drug inhibition of signalling molecules

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Imatinib: a selective tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

STI-571: an anticancer protein-tyrosine kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Glivec (STI571, imatinib), a rationally developed, targeted anticancer drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Dynamics of chronic myeloid leukaemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Second generation inhibitors of BCR-ABL for the treatment of imatinib-resistant chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Analysis of the structural basis of specificity of inhibition of the Abl kinase by STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mutation in the ATP-binding site of BCR-ABL in a patient with chronic myeloid leukaemia with increasing resistance to STI571.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

High frequency of point mutations clustered within the adenosine triphosphate-binding region of BCR/ABL in patients with chronic myeloid leukemia or Ph-positive acute lymphoblastic leukemia who develop imatinib (STI571) resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Advances in the structural biology, design and clinical development of Bcr-Abl kinase inhibitors for the treatment of chronic myeloid leukaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

2-aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (d

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

An efficient rapid system for profiling the cellular activities of molecular libraries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

The structure of Dasatinib (BMS-354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Dasatinib induces complete hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in blast crisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

21 January 2018

KIT mutations in GIST.

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

STI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Combined surgical and molecular therapy: the gastrointestinal stromal tumor model

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Imatinib mesylate (STI-571 Glivec, Gleevec) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are unselected for a molecular target. Results from an EORTC Soft Tissue and Bone Sa

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Analysis of KIT mutations in sporadic and familial gastrointestinal stromal tumors: therapeutic implications through protein modeling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Gastrointestinal stromal tumor (GIST).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Gastric GI stromal tumors (GISTs): the role of surgery in the era of targeted therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

c-erbB-2 oncogene as a prognostic marker in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

The ErbB/HER receptor protein-tyrosine kinases and cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Herceptin: mechanisms of action and resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Phase II study of weekly docetaxel and trastuzumab for patients with HER-2-overexpressing metastatic breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Insulin-like growth factor-I receptor/human epidermal growth factor receptor 2 heterodimerization contributes to trastuzumab resistance of breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Combining lapatinib (GW572016), a small molecule inhibitor of ErbB1 and ErbB2 tyrosine kinases, with therapeutic anti-ErbB2 antibodies enhances apoptosis of ErbB2-overexpressing breast cancer cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Lapatinib plus capecitabine for HER2-positive advanced breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Trastuzumab in the treatment of non-small cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Lung cancer: intragenic ERBB2 kinase mutations in tumours

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Somatic mutations of the HER2 kinase domain in lung adenocarcinomas.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Trastuzumab in the treatment of advanced non-small-cell lung cancer: is there a role? Focus on Eastern Cooperative Oncology Group study 2598.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Trastuzumab in combination with cisplatin and gemcitabine in patients with Her2-overexpressing, untreated, advanced non-small cell lung cancer: report of a phase II trial and findings regarding optimal identification of patients with Her2-overexpres

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Lack of trastuzumab activity in nonsmall cell lung carcinoma with overexpression of erb-B2: 39810: a phase II trial of Cancer and Leukemia Group B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

EGFR and cancer prognosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Inhibitors of epidermal-growth-factor receptors: a review of clinical research with a focus on non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected].

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Erlotinib in previously treated non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Detection of response-predicting mutations in the kinase domain of the epidermal growth factor receptor gene in cholangiocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Somatic mutations of EGFR gene in squamous cell carcinoma of the head and neck

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Somatic mutations of epidermal growth factor receptor in colorectal carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Phase II study of gefitinib in patients with relapsed or persistent ovarian or primary peritoneal carcinoma and evaluation of epidermal growth factor receptor mutations and immunohistochemical expression: a Gynecologic Oncology Group Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Epidermal growth factor receptor variant III mutations in lung tumorigenesis and sensitivity to tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Update on epidermal growth factor receptor mutations in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Clinical course of patients with non-small cell lung cancer and epidermal growth factor receptor exon 19 and exon 21 mutations treated with gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Epidermal growth factor receptor mutations are associated with gefitinib sensitivity in non-small cell lung cancer in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Gefitinib for non-small-cell lung cancer patients with epidermal growth factor receptor gene mutations screened by peptide nucleic acid-locked nucleic acid PCR clamp

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Prediction of sensitivity of advanced non-small cell lung cancers to gefitinib (Iressa, ZD1839).

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Increased HER2 gene copy number is associated with response to gefitinib therapy in epidermal growth factor receptor-positive non-small-cell lung cancer patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Colorectal cancer: mutations in a signalling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Novel inhibitors of the v-raf murine sarcoma viral oncogene homologue B1 (BRAF) based on a 2,6-disubstituted pyrazine scaffold

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

In vitro differential sensitivity of melanomas to phenothiazines is based on the presence of codon 600 BRAF mutation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

Mitochondrial regulation by c-Myc and hypoxia-inducible factor-1 alpha controls sensitivity to econazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party o

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FTPJ.2008.8

21 January 2018

Identifiers

DOI

10.1038/TPJ.2008.8

1 reference

19 August 2017

1 reference

PubMed ID

18679398